Maximizing pipeline eNPV with Accelerator™ Drug Development
Bringing a new therapy to market is increasingly challenging, timely and costly, with development costs ranging from $1.3 billion and $2.8 billion, and timelines stretching over a decade. With investors and patients demanding faster results, improving efficiency in drug development is now a strategic imperative for biotech and biopharmaceutical leaders.
Many companies still rely on a flexible, yet fragmented multi-vendor model, contracting separately for manufacturing, clinical research, laboratory services and supply chain management. This approach often creates silos, duplicative processes and handoffs that cost a company both precious time and execution consistency – all of which contribute to delays at nearly every stage.
One promising path forward is integration: aligning manufacturing, clinical research and supply chain services under a single strategic partner. This white paper explores:
- How successful integrated frameworks are reshaping the financial calculus for leaders in drug development – and why now is the time to embrace a model designed for speed and value creation.
- The strategic advantages of using expected net present value (eNPV) for portfolio management and investment decisions.
- The speed made possible through an integrated, single vendor model, which enables greater value creation by reducing time-to-fail, time-to-sale or time-to-market for pipeline assets.
- How partnering with Thermo Fisher Scientific, a world leader in serving science, gives companies the speed, integration and confidence in execution necessary to support their unique drug development journey using Accelerator™ Drug Development 360° CDMO and CRO solutions.
